KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Common Equity: 2020-2025

Historic Common Equity for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $964.0 million.

  • AbCellera Biologics' Common Equity fell 10.58% to $964.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.0 million, marking a year-over-year decrease of 10.58%. This contributed to the annual value of $1.1 billion for FY2024, which is 8.35% down from last year.
  • Per AbCellera Biologics' latest filing, its Common Equity stood at $964.0 million for Q3 2025, which was down 4.27% from $1.0 billion recorded in Q2 2025.
  • AbCellera Biologics' Common Equity's 5-year high stood at $1.3 billion during Q3 2022, with a 5-year trough of $953.4 million in Q3 2021.
  • In the last 3 years, AbCellera Biologics' Common Equity had a median value of $1.1 billion in 2024 and averaged $1.1 billion.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 31.13% in 2022, then dropped by 10.58% in 2025.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Common Equity stood at $1.0 billion in 2021, then climbed by 20.23% to $1.2 billion in 2022, then decreased by 6.56% to $1.2 billion in 2023, then declined by 8.35% to $1.1 billion in 2024, then declined by 10.58% to $964.0 million in 2025.
  • Its last three reported values are $964.0 million in Q3 2025, $1.0 billion for Q2 2025, and $1.0 billion during Q1 2025.